Equity Profile

CHE

Chemed Corporation

Health CareHealth Care Services$6.5B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Chemed Corporation operates in the health care sector, providing services primarily in hospice and palliative care. With a market cap of $7 billion, the company plays a crucial role in delivering compassionate care to patients with serious illnesses, which is increasingly important as the population ages.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Expected to be around $5.65.

Revenue Growth

Revenue growth reflects the company's ability to expand its services and capture market share in the health care sector.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CHE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.95%

Avg Stock Reaction

+0.49%

Last Quarter Recap

In Q1-2026, Chemed reported an EPS of $5.65, surpassing expectations by 16.49%. The stock reacted positively, increasing by 2.63% the following day.

Management Promises & Guidance

Focus on improving patient care and service delivery.
Commitment to expanding hospice services.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, analysts expect Chemed to continue its trend of beating EPS estimates, given its strong historical performance. However, there is uncertainty around revenue growth and patient volume.

Bull Case

If Chemed delivers strong EPS and shows significant revenue growth, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses EPS expectations or shows stagnant revenue growth, it could lead to a negative reaction from the market.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $5.65.

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its services and capture market share in the health care sector.

Patient Volume

Not available.

An increase in patient volume can indicate strong demand for Chemed's services, which is vital for future revenue growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be crucial in determining if Chemed can maintain its trend of beating expectations and reassure investors.

How has patient volume changed compared to last quarter?

Understanding patient volume trends will provide insights into the company's growth potential and demand for its services.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Chemed's ability to expand its patient base, given its recent investments in service delivery improvements.

Supporting Evidence

Chemed has a history of beating EPS estimates, indicating strong operational management.

Recent trends in the health care sector show increasing demand for hospice services.

Options pricing suggests a significant move, indicating that investors are anticipating a pivotal shift.

Key Risk

If patient volume exceeds expectations, it could lead to a significant upward revision in growth forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Chemed can sustain its growth trajectory amidst increasing competition in health care services.

Bull Confirmed If

An EPS of $5.75 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±13.24%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±13.2% while CHE has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

33.0%

Calls (400)P/C Ratio: 0.33Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Chemed beats expectations, history suggests the stock could rise by around 0.76% on the first day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious guidance, the stock may remain flat or see a slight decline.

Miss

If Chemed misses EPS expectations, history suggests a potential decline of about 0.33%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on patient volume growth compared to last quarter.
2Management's commentary on operational efficiencies and cost management.
3Insights into the competitive landscape and Chemed's market positioning.
4Details on any new service offerings or expansions planned.
5Guidance on revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Expected to be around $5.65.

Revenue Growth

Revenue growth reflects the company's ability to expand its services and capture market share in the health care sector.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CHE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.95%

Avg Stock Reaction

+0.49%

Last Quarter Recap

In Q1-2026, Chemed reported an EPS of $5.65, surpassing expectations by 16.49%. The stock reacted positively, increasing by 2.63% the following day.

Management Promises & Guidance

Focus on improving patient care and service delivery.
Commitment to expanding hospice services.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, analysts expect Chemed to continue its trend of beating EPS estimates, given its strong historical performance. However, there is uncertainty around revenue growth and patient volume.

Bull Case

If Chemed delivers strong EPS and shows significant revenue growth, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses EPS expectations or shows stagnant revenue growth, it could lead to a negative reaction from the market.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $5.65.

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its services and capture market share in the health care sector.

Patient Volume

Not available.

An increase in patient volume can indicate strong demand for Chemed's services, which is vital for future revenue growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be crucial in determining if Chemed can maintain its trend of beating expectations and reassure investors.

How has patient volume changed compared to last quarter?

Understanding patient volume trends will provide insights into the company's growth potential and demand for its services.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Chemed's ability to expand its patient base, given its recent investments in service delivery improvements.

Supporting Evidence

Chemed has a history of beating EPS estimates, indicating strong operational management.

Recent trends in the health care sector show increasing demand for hospice services.

Options pricing suggests a significant move, indicating that investors are anticipating a pivotal shift.

Key Risk

If patient volume exceeds expectations, it could lead to a significant upward revision in growth forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Chemed can sustain its growth trajectory amidst increasing competition in health care services.

Bull Confirmed If

An EPS of $5.75 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±13.24%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±13.2% while CHE has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

33.0%

Calls (400)P/C Ratio: 0.33Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Chemed beats expectations, history suggests the stock could rise by around 0.76% on the first day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious guidance, the stock may remain flat or see a slight decline.

Miss

If Chemed misses EPS expectations, history suggests a potential decline of about 0.33%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on patient volume growth compared to last quarter.
2Management's commentary on operational efficiencies and cost management.
3Insights into the competitive landscape and Chemed's market positioning.
4Details on any new service offerings or expansions planned.
5Guidance on revenue expectations for the next quarter.